Login to Your Account



SIDE EFFECT SPECS ON DECK

Air pair Esbriet, Ofev tied for FDA first in IPF; Roche rolling price dice but BI yet to disclose

By Randy Osborne
Staff Writer

Friday, October 17, 2014
Nearly simultaneous approvals by the FDA of two oral drugs for idiopathic pulmonary fibrosis (IPF) set the market buzzing about the potential competitive and therapeutic advantages of each, as Roche AG prepared to launch its oral Esbriet (pirfenidone) and Boehringer Ingelheim GmbH (BI) lined up its oral kinase inhibitor, Ofev (nintedanib).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription